A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer

PURPOSE: Notch signaling dysregulation is implicated in the development of pancreatic adenocarcinoma (PDAC). Tarextumab is a fully human IgG2 antibody that inhibits Notch2/3 receptors. PATIENTS AND METHODS: Aphase 2, randomized, placebo‐controlled, multicenter trial evaluated the activity of tarextu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Hu, Zishuo Ian, Bendell, Johanna C., Bullock, Andrea, LoConte, Noelle K., Hatoum, Hassan, Ritch, Paul, Hool, Hugo, Leach, Joseph W., Sanchez, James, Sohal, Davendra P. S., Strickler, John, Patel, Ravindranath, Wang‐Gillam, Andrea, Firdaus, Irfan, Yu, Kenneth H., Kapoun, Ann M., Holmgren, Eric, Zhou, Lei, Dupont, Jakob, Picozzi, Vincent, Sahai, Vaibhav, O'Reilly, Eileen M.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6718621/
https://ncbi.nlm.nih.gov/pubmed/31347292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2425
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados